Related Experiment Video
Updated: Jul 12, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors
Alexander Malik1, Muhammad N Yousaf2, Sami Samiullah3
1Department of Medicine, Summa Health System, Akron, OH, United States.
Simultaneous immune checkpoint inhibitor (ICI)-associated hepatitis and colitis is a rare but serious adverse event. Early recognition and prompt treatment are crucial for managing these overlapping toxicities in cancer patients.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Immune checkpoint inhibitors (ICIs) like CTLA-4, PD-1, and PD-L1 inhibitors are vital in cancer therapy.
- Immune system hyperactivation can lead to adverse events, including organ-specific toxicities.
- Simultaneous hepatotoxicity and colitis from ICIs are rare and often present with nonspecific symptoms.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Hepatic Drug Excretion: Influencing Factors

